Phase 1/2a Clinical Trial to Assess the Safety of HB-adMSCs for the Treatment of Rheumatoid Arthritis

Inclusion Criteria: * Adult male or female between the ages of 18 and 65 * Patients have active RA as confirmed by the following criteria: * ≥ 6 swollen joints and ≥ 6 tender joints at screening (68-joint count) * Abnormal CRP result OR abnormal ESR result at screening. Abnormal CRP result at screening OR abnormal ESR defined as: * CRP \> 4.9 mg/L or ESR \> 10mm/hr for men, \> 20mm/hr for women * Patients without current established treatment, or if being treated, patients who are on a stable dose of RA therapy regimen for ≥ 4 weeks prior to screening Exclusion Criteria: * Inability to understand and provide signed informed consent * Pregnancy, lactation, or, if female of childbearing potential, positive serum β-hCG at screening. * Currently diagnosed any malignant neoplasm. Any patient who was successfully treated for cancer and has been disease-free, with no recurrence, for at least 5 years, will be considered. * Uncontrolled systemic illness, including, but not limited to: hypertension (systolic \>150 mm Hg or diastolic \>95 mm Hg); diabetes; renal, hepatic, or cardiac failure or any laboratory abnormality that poses a safety risk to the subject such as: * Hemoglobin ≤8.5 g/dL * White blood cells (WBCs) ≤3,500/mm3 (3.5 G/L) * Any other illness which, in the opinion of the investigator, characterizes the subject as not being a good candidate for the study * Participation in another study with an investigational drug or device within 4 weeks prior to treatment or 5 half-lives of the investigational product used (whichever is longer). * Positive results of hepatitis B surface antigen (HBsAg), hepatitis B surface antibody (HBsAb), hepatitis B core antibody (HBcAb), hepatitis C antibody (HCV Ab), and/or human immunodeficiency virus antibody (HIV Ab) tests at screening (excluding patients who are tested positive for HBsAb alone due to a hepatitis B vaccination). * Positive history of Treponema pallidum.